Dujardin Makeda

Dujardin Makeda

Auto-generated profile, based on publicly available information

Dujardin Makeda

Faculty of Medicine Université Libre des Pays des Grands Lacs Goma DR Congo

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
DMDujardin Makeda
Dujardin Makeda
HYHermann Yokolo
Hermann Yokolo
JEJoshua Ekouo
Joshua Ekouo
LNLéopoldine Sybile Tatsadjieu Ngoune
Léopoldine Sybile Tatsadjieu Ngoune
AAAymar Akilimali
Aymar Akilimali
Endocrine disruptors (EDs) are a heterogeneous group of natural or synthetic chemicals capable of interfering with hormonal regulation. Widely present in plastics, cosmetics, pesticides, food packaging, and household products, they contribute to constant human exposure. Compounds such as bisphenol A, phthalates, parabens, dioxins, and certain pesticides are among the most studied. Their mechanisms of action include interaction with hormone receptors, modulation of gene expression through epigenetic changes, disruption of steroidogenesis, and interference with the hypothalamic–pituitary–gonadal axis. Evidence from animal and human studies suggests that EDs may reduce ovarian reserve, impair oocyte maturation, alter ovulation and implantation, and contribute to infertility. Associations have also been observed with polycystic ovary syndrome, endometriosis, and poorer outcomes of assisted reproductive techniques. Despite these findings, human data remain largely observational, with methodological limitations such as variable exposure assessment, lack of standardized biomarkers, and the unaddressed “cocktail effect.” Strengthening preventive strategies, regulatory measures, and further research is essential to better understand and mitigate the risks EDs pose to female reproductive health.

1 September 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
DMDujardin Makeda
Dujardin Makeda
EJEkouo Joshua
Ekouo Joshua
CTChristian Tague
Christian Tague
HYHermann Yokolo
Hermann Yokolo
AAAymar Akilimali
Aymar Akilimali

28 November 2024 in New Microbes and New Infections
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
MBMayar Budair
Mayar Budair
MRMaher Ali Rusho
Maher Ali Rusho
AKAdolphe Karegeya
Adolphe Karegeya
MMMc Juan Muco Mugisha
Mc Juan Muco Mugisha
AAAymar Akilimali
Aymar Akilimali

29 March 2026 in Health Science Reports
Verified
Journal Article
Open access
SDStanis Donnang
Stanis Donnang
HYHermann Yokolo
Hermann Yokolo
DMDujardin Makeda
Dujardin Makeda
JEJoshua Ekouo
Joshua Ekouo
ZSZubayer Shams
Zubayer Shams
CTChristian Tague
Christian Tague
Background: The Democratic Republic of Congo (DRC) faces a “triple burden” of public health threats which includes climate change, protracted armed conflict, and the under‐recognized spread of arboviral diseases. Arboviruses, such as dengue, chikungunya, Zika, and yellow fever, are transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Certain factors, like environmental changes, population displacement, and inadequate vector control, have created conditions that favor sustained transmission. Methods: The narrative review was conducted to compile evidence on factors influencing arbovirus spread in the DRC and to identify the priority causes of prevention. A comprehensive literature search was done in PubMed and Google Scholar for studies, NGO reports, and government documents published between 2019 and 2025 in French or English, focusing on human populations in the DRC or similar contexts. Results: Key findings demonstrate that yellow fever remains endemic, with recurrent outbreaks and a case fatality rate of up to 21.3% in past years. Seroprevalence studies show significant dengue exposure (up to 41% in Kinshasa), multiple chikungunya epidemics which affected millions, and intermittent Zika virus exposure. On the other hand, adverse climate change alters vector ecology and increases transmission potential through drought, floods, rising temperatures, and deforestation. Armed conflict proved to play a major role in the large‐scale displacement of people into overcrowded, unsanitary environments. This, as a result, disrupts the surveillance and control programmes and increases vulnerability to arboviruses. Conclusion: The convergence of climate change, armed conflict, and arbovirus transmission poses a growing public health threat in the DRC. Strengthening integrated and reinforced surveillance, augmenting diagnostic capacity, applying sustainable vector control, and advocating climate and security considerations in health policy are essential and mandatory. Without coordinated and multidisciplinary action, the silent and hazardous spread of arboviruses will remain consistent to weaken and compromise health system resilience.

25 June 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
HYHermann Yokolo
Hermann Yokolo
DMDujardin Makeda
Dujardin Makeda
JEJoshua Ekouo
Joshua Ekouo
EKElie Kihanduka
Elie Kihanduka
AAAymar Akilimali
Aymar Akilimali
An abstract is unavailable. This article is available as a PDF only.

30 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
JEJoshua Ekouo
Joshua Ekouo
DMDujardin Makeda
Dujardin Makeda
HYHermann Yokolo
Hermann Yokolo
JOJones Onesime
Jones Onesime
AAAymar Akilimali
Aymar Akilimali
Therapeutic cancer vaccines represent a promising immunotherapy approach aimed at treating existing cancers by stimulating the patient’s immune system to target tumor cells. Unlike prophylactic vaccines, therapeutic vaccines are administered after cancer diagnosis and focus on inducing specific cytotoxic CD8 + T cell responses against tumor-associated antigens or tumor-specific neoantigens. These antigens are presented by antigen-presenting cells, such as dendritic cells, to activate an immune attack. However, the efficacy of therapeutic vaccines is often limited by immune tolerance, tumor heterogeneity, and an immunosuppressive tumor microenvironment, necessitating combination with other treatments like immune checkpoint inhibitors or chemotherapy. Multiple vaccine platforms are under investigation, including peptide/protein-based, DNA/messenger RNA (mRNA)-based, dendritic cell vaccines, viral vector vaccines, and personalized neoantigen vaccines that leverage next-generation sequencing for precision targeting. Clinical trials target a range of cancers, including melanoma, gynecologic, breast, pancreatic, liver, glioblastoma, and lung cancers, with results showing immune activation but modest clinical efficacy. Key challenges include immune evasion, variability in patient response, manufacturing complexities, high cost, and lack of predictive biomarkers. Technological advances in nanoparticle delivery, potent adjuvants, mRNA platforms, and combination immunotherapies are being explored to enhance vaccine performance. In low-resource settings, barriers such as limited access to advanced diagnostics and clinical trials necessitate tailored strategies to ensure equitable vaccine deployment. Overall, therapeutic cancer vaccines hold potential to become integrated into standard oncology protocols, especially for adjuvant therapy and recurrence prevention, with an emphasis on personalized and accessible immunotherapies to transform cancer management globally.